Atopic Dermatitis (Eczema)
Atopic dermatitis, commonly called eczema, is a chronic, relapsing-remitting inflammatory skin disorder characterized by intense pruritus, xerosis and eczematous lesions that vary with age and disease stage. In infants lesions favour the cheeks, scalp and extensor surfaces; in children and adults they shift to flexural creases, hands, ankles and eyelids, often with lichenification from habitual scratching. The condition represents the cutaneous component of the atopic march that can progress to food allergy, allergic rhinitis and asthma, and its severe itch impairs sleep and quality of life for patients and caregivers.
Symptoms
Hallmark features are severe pruritus often worse at night, dry scaly skin, erythematous papules that may ooze and crust during acute flares, and thickened hyperpigmented lichenified plaques after chronic scratching. Scratching produces excoriations and perilabial rhagades, and Dennie-Morgan infraorbital folds or hyperlinear palms may be present. Many patients have coexistent allergic rhinitis, asthma or food allergy manifesting as immediate hives or gastrointestinal symptoms after ingestion.
Risk Factors
Positive family history of atopy, FLG null mutations, northern European or Asian ancestry, urban living with low microbial diversity, premature birth, formula feeding without early allergen introduction, hard water exposure, low vitamin D, obesity, female sex in adulthood and frequent use of detergents or harsh soaps increase susceptibility. Environmental triggers that exacerbate disease include wool clothing, sweating, cold dry air, pollen, house-dust-mite allergens, pet dander, stress and infections.
Diagnosis
Diagnosis is clinical: essential criteria include chronic pruritic dermatitis with typical morphology and distribution plus personal or family history of atopy. No single laboratory test confirms the condition although elevated total IgE, peripheral eosinophilia and FLG mutation analysis support the diagnosis. Skin-prick or specific-IgE tests identify allergic sensitisation when food or aeroallergen triggers are suspected. Swabs or cultures detect Staphylococcus aureus in impetiginised lesions. Biopsy is rarely required except to exclude psoriasis, seborrhoeic dermatitis, scabies or cutaneous T-cell lymphoma.
Treatment
Cornerstones of therapy are daily restoration of the skin barrier, elimination of triggers and targeted anti-inflammatory treatment. Liberal application of fragrance-free emollients or petrolatum at least twice daily and within three minutes after bathing forms the foundation. Mild to moderate flares respond to low- or medium-potency topical corticosteroids such as hydrocortisone 2.5 % or triamcinolone 0.1 % ointment applied twice daily for seven to fourteen days then tapered; calcineurin inhibitors tacrolimus 0.03 – 0.1 % or pimecrolimus 1 % offer steroid-sparing control for sensitive areas like face and groin and for maintenance twice-weekly proactive therapy. Crisaborole 2 % phosphodiesterase-4 inhibitor ointment relieves mild disease. Moderate to severe atopic dermatitis refractory to optimized topical care is treated systemically: dupilumab, an IL-4Rα monoclonal antibody, improves itch and lesions and is approved from six months of age; tralokinumab and lebrikizumab target IL-13 in adults. Janus-kinase inhibitors—abrocitinib, upadacitinib (oral) and ruxolitinib cream—rapidly alleviate pruritus but require laboratory monitoring for lipid, creatine phosphokinase and thrombotic risk. Short courses of oral corticosteroids or cyclosporine induce remission but carry rebound and toxicity. Wet-wrap therapy with topical steroids under damp bandages provides dramatic short-term relief in severe flares. Chronic colonisation or secondary infection by S. aureus is treated with bleach baths, mupirocin or systemic antibiotics as indicated. Antihistamines have limited efficacy for itch but sedating agents may aid sleep. Behavioural sleep and itch-management strategies, stress-reduction techniques and caregiver education are integral components.
Outlook
Approximately 50 % of children achieve complete remission by adolescence, yet many retain a predisposition to dry irritable skin and relapse in adulthood. Severe persistent disease predicts allergic rhinitis and asthma development and is associated with depression, anxiety and learning impairment. Biologic and targeted oral therapies have revolutionised control and quality of life for moderate to severe cases with favourable long-term safety profiles.
Complications
Recurrent bacterial impetigo, eczema herpeticum (HSV), molluscum contagiosum, diminished quality of life, sleep disturbance, attention deficits, anxiety, depression, higher cardiovascular risk markers, ocular complications such as keratoconus and cataracts, and allergic hand dermatitis from chronic topical exposure may develop.
Prevention
Daily emollient use from birth in high-risk infants reduces eczema incidence by up to 30 %. Exclusive breastfeeding for three to four months, early introduction of peanut and egg at four to six months, avoidance of overheating and tobacco smoke, and maintenance of indoor humidity 40–50 % further decrease risk. For established disease, trigger avoidance, continuous moisturization, proactive twice-weekly anti-inflammatory application to previous hotspots and treatment of allergic rhinitis or food allergy prevent exacerbations.
Support
Individuals should take lukewarm 10-minute baths or showers using gentle non-soap cleansers, pat dry and immediately apply thick emollient; keep fingernails short, wear cotton gloves or pyjamas at night to reduce scratching, launder clothing in fragrance-free detergent, use humidifiers in dry climates, manage stress with mindfulness or cognitive-behavioural therapy, and adhere to prescribed medications even when skin appears clear through proactive maintenance. Structured educational programmes and eczema action plans empower families to identify early flare signs and intervene promptly.
Sources
The information presented above is supported by reputable medical sources and research publications. These references provide additional clinical insights and evidence-based findings for healthcare professionals and individuals seeking comprehensive understanding of this medical condition.
